These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

129 related articles for article (PubMed ID: 38683528)

  • 21. Pharmaceuticals and medical devices: cost savings. End-of-year issue brief.
    Health Policy Tracking Service, A Service of Thomson Reuters/West
    Issue Brief Health Policy Track Serv; 2011 Jan; ():1-21. PubMed ID: 21374837
    [No Abstract]   [Full Text] [Related]  

  • 22. The Problem of Limited-Supply Agreements for Medicare Price Negotiation.
    Gabriele SME; Feldman WB
    JAMA; 2023 Oct; 330(13):1223-1224. PubMed ID: 37713185
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Fake pharmaceuticals: how they and relevant legislation or lack thereof contribute to consistently high and increasing drug prices.
    Moken MC
    Am J Law Med; 2003; 29(4):525-42. PubMed ID: 15119247
    [No Abstract]   [Full Text] [Related]  

  • 24. Global pharmaceutical development and access: critical issues of ethics and equity.
    Lage A
    MEDICC Rev; 2011 Jul; 13(3):16-22. PubMed ID: 21778954
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Sir Michael Rawlins on being NICE--and fair--about drug development and availability. Interview by Daniel Clarke.
    Rawlins SM
    Drug Discov Today; 2005 Mar; 10(6):383-6. PubMed ID: 15808816
    [No Abstract]   [Full Text] [Related]  

  • 26. FDA chief attacks Canada's drug price controls.
    Webster P
    Lancet; 2003 Nov; 362(9398):1816. PubMed ID: 14661624
    [No Abstract]   [Full Text] [Related]  

  • 27. Are rich nations up for drug reform?
    Check E
    Nature; 2006 May; 441(7090):135. PubMed ID: 16688137
    [No Abstract]   [Full Text] [Related]  

  • 28. The 340B Drug Pricing Program: an opportunity for savings, if covered entities such as disproportionate share hospitals and federally qualified health centers know how to interpret the regulations.
    Werling K; Abraham S; Strelec J
    Health Care Law Mon; 2007 Aug; ():3-12. PubMed ID: 17955590
    [No Abstract]   [Full Text] [Related]  

  • 29. Paying a high price for low costs: why there should be no legal constraints on the profits that can be made on drugs for tropical diseases.
    Sonderholm J
    J Med Ethics; 2009 May; 35(5):315-9. PubMed ID: 19407038
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Argentina appoints new health minister while health system takes the strain.
    Iglesias-Rogers G
    Lancet; 2002 Jan; 359(9303):330. PubMed ID: 11830215
    [No Abstract]   [Full Text] [Related]  

  • 31. 340B program presents opportunities--and challenges.
    Keough CL; Webster SA
    Healthc Financ Manage; 2009 Nov; 63(11):42-4, 46, 48. PubMed ID: 19891397
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Pharmaceuticals and medical devices: business practices.
    Steiner DJ
    Issue Brief Health Policy Track Serv; 2013 Dec; ():1-36. PubMed ID: 24482889
    [No Abstract]   [Full Text] [Related]  

  • 33. Pharmaceuticals and medical devices: cost savings.
    ; Steiner DJ
    Issue Brief Health Policy Track Serv; 2012 Jan; ():1-37. PubMed ID: 22403843
    [No Abstract]   [Full Text] [Related]  

  • 34. The cost and availability of prescription drugs--what can we do in Massachusetts?
    Carpenter NW; Kedikoglou S
    Issue Brief (Mass Health Policy Forum); 1999 May; (4):1-41. PubMed ID: 12769091
    [No Abstract]   [Full Text] [Related]  

  • 35. The cost of drug coupons.
    Grande D
    JAMA; 2012 Jun; 307(22):2375-6. PubMed ID: 22692167
    [No Abstract]   [Full Text] [Related]  

  • 36. Retail price regulation and innovation: reference pricing in the pharmaceutical industry.
    Bardey D; Bommier A; Jullien B
    J Health Econ; 2010 Mar; 29(2):303-16. PubMed ID: 20053474
    [TBL] [Abstract][Full Text] [Related]  

  • 37. New prescription for the Spanish drug sector: fighting against public deficit without wasting ammunition.
    Antoñanzas F; Gómez P
    Pharmacoeconomics; 2010; 28(11):977-80. PubMed ID: 20936881
    [No Abstract]   [Full Text] [Related]  

  • 38. The 340B Drug Pricing Program: an opportunity for savings, if covered entities such as disproportionate share hospitals and federally qualified health centers know how to interpret the regulations.
    Werling K; Abraham S; Strelec J
    J Health Care Finance; 2007; 34(2):57-70. PubMed ID: 18972994
    [No Abstract]   [Full Text] [Related]  

  • 39. Prices of 18 new drug formulations are capped in India.
    Travasso C
    BMJ; 2015 Nov; 351():h6006. PubMed ID: 26553651
    [No Abstract]   [Full Text] [Related]  

  • 40. Drug prices and trends before and after requesting compulsory licenses: the Ecuadorian experience.
    Ortiz-Prado E; Cevallos-Sierra G; Teran E; Vasconez E; Borrero-Maldonado D; Ponce Zea J; Simbaña-Rivera K; Gómez-Barreno L
    Expert Opin Ther Pat; 2019 Aug; 29(8):653-662. PubMed ID: 31298053
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.